Reply: Appropriate prospective trials are warranted to determine differences between exon 19 deletions and L858R EGFR mutations in non-small cell lung cancer

por Asahina, H, Yamazaki, K, Kinoshita, I
Publicado 2007

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

por Asahina, H, Yamazaki, K, Kinoshita, I, Sukoh, N, Harada, M, Yokouchi, H, Ishida, T, Ogura, S, Kojima, T, Okamoto, Y, Fujita, Y, Dosaka–akita, H, Isobe, H, Nishimura, M
Publicado 2006